LGNDLigand Pharmaceuticals Incorporated

$4B

FY 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$141M+29.5% YoY

Gross Profit

$136M96.2% margin

Operating Income

$68M48.2% margin

Net Income

$13M8.9% margin

EPS (Diluted)

$0.53

Cash Flow

Operating Cash Flow

$94M

Free Cash Flow

$86M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$671M

Total Liabilities

$252M

Stockholders' Equity

$419M

Cash & Equivalents

$202M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$141M	$109M	+29.5%
Gross Profit	$136M	$103M	+31.3%
Operating Income	$68M	$44M	+55.1%
Net Income	$13M	-$2M	+867.5%

LGND FY 2017 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena